Manifaxine

From Self-sufficiency
Revision as of 06:27, 6 March 2010 by حسن علي البط (Talk) (Quick-adding category Morpholines (using HotCat))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Manifaxine
200px
Systematic (IUPAC) name
(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol
Identifiers
CAS Number 135306-39-7
ATC code none
PubChem CID 60829
Chemical data
Formula C12H15F2NO2
Molar mass 243.249 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, the active metabolite of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications,[1][2] but no results have been reported following these initial trials and its current status is unclear.

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill JM, Laurenza A, Barrows CE, Webster CJ, Stotka CJ, Asgharnejad M. GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. Journal of the American Academy of Child and Adolescent Psychiatry. 2002 Aug;41(8):914-20. PMID 12162627
  2. Spraggs CF, Pillai SG, Dow D, Douglas C, McCarthy L, Manasco PK, Stubbins M, Roses AD. Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenetics and Genomics. 2005 Dec;15(12):883-9. PMID 16272960